Last reviewed · How we verify

Recombinant FIX Fc fusion product Alprolix

Emory University · Phase 1 active Small molecule Quality 0/100

Recombinant FIX Fc fusion product Alprolix is a Small molecule drug developed by Emory University. It is currently in Phase 1 development. Also known as: Alprolix.

At a glance

Generic nameRecombinant FIX Fc fusion product Alprolix
Also known asAlprolix
SponsorEmory University
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Recombinant FIX Fc fusion product Alprolix

What is Recombinant FIX Fc fusion product Alprolix?

Recombinant FIX Fc fusion product Alprolix is a Small molecule drug developed by Emory University.

Who makes Recombinant FIX Fc fusion product Alprolix?

Recombinant FIX Fc fusion product Alprolix is developed by Emory University (see full Emory University pipeline at /company/emory-university).

Is Recombinant FIX Fc fusion product Alprolix also known as anything else?

Recombinant FIX Fc fusion product Alprolix is also known as Alprolix.

What development phase is Recombinant FIX Fc fusion product Alprolix in?

Recombinant FIX Fc fusion product Alprolix is in Phase 1.

Related